Dr Elias Jabbour speaks to ecancer about the phase 3 Phallcon Study. This study compared ponatinib to imatinib in patients with newly diagnosed Ph+ ALL.

The study found that ponatinib was superior to imatinib in combination with reduced-intensity chemotherapy in the front-line setting for patients with Ph+ ALL, with a clinically significantly higher MRD-neg complete response rate at the end of induction.

The benefit of this regimen was noticed across all subgroups, particularly for patients ≥60 years and for those with the BCR::ABL1 p190 variant.